Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis

This publication has 44 references indexed in Scilit:

• Network Meta-Analysis Using R: A Review of Currently Available Automated Packages
  PLOS ONE, 2014
• A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
  PLOS ONE, 2014
• Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
  Journal of Clinical Oncology, 2014
• American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
  Journal of Clinical Oncology, 2014
• Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
  BMC Medical Research Methodology, 2013
• Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
  Value in Health, 2011
• Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy
  Journal of Thoracic Oncology, 2010
• Combination of direct and indirect evidence in mixed treatment comparisons
  Statistics in Medicine, 2004
• Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses
  BMJ, 2003
• Network meta‐analysis for indirect treatment comparisons
  Statistics in Medicine, 2002